Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / PAVM - PAVmed: Long Term Investment Case Remains Despite Weak Q2

PAVM - PAVmed: Long Term Investment Case Remains Despite Weak Q2

PAVmed Inc.
  • EsoGuard/EsoCheck showed pretty slow growth in Q2 but momentum should improve as the company starts targeting consumers and PCPs directly and launches into Europe.
  • Momentum for PAVM's pipeline products remains strong, and the company remains on track to get 3-4 products on the market by the end of 2022.
  • In addition, subsidiary Veris Health is in talks with Microsoft which could lead to an eventual partnership.
  • The valuation of the company remains low at $500mil despite the incredible momentum the company is showing and the clear disruptiveness of each of its products.

For further details see:

PAVmed: Long Term Investment Case Remains Despite Weak Q2
Stock Information
Company Name: PAVmed Inc.
Stock Symbol: PAVM
Market: NASDAQ
Website: pavmed.com
Menu
PAVM PAVM Quote PAVM Short PAVM News PAVM Articles PAVM Message Board
Get PAVM Alerts

News, Short Squeeze, Breakout and More Instantly...